Starton Therapeutics Receives Authorization From The FDA To Proceed With STAR-LLD Lenalidomide Phase 1b Clinical Trial In Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Starton Therapeutics has received FDA authorization to proceed with its Phase 1b STAR-LLD clinical trial for multiple myeloma. The treatment will replace oral Revlimid with STAR-LLD and will be combined with Velcade and dexamethasone. Starton has signed an agreement for a business combination with Healthwell Acquisition Corp. I (NASDAQ:HWEL).
June 12, 2023 | 8:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Healthwell Acquisition Corp. I (NASDAQ:HWEL) has signed a business combination agreement with Starton Therapeutics, which has received FDA authorization for its Phase 1b STAR-LLD clinical trial in multiple myeloma.
The FDA authorization for Starton Therapeutics' Phase 1b STAR-LLD clinical trial is a positive development for the company, which has signed a business combination agreement with Healthwell Acquisition Corp. I (NASDAQ:HWEL). This news is likely to have a positive short-term impact on HWEL's stock price, as it indicates progress in Starton's clinical trials and potential future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100